C. Dean Maglaris, CEO, Chairman of the Board of Managers. Mr. Maglaris is an experienced senior executive in the pharmaceutical industry, having spent over 33 years with Pfizer Inc. in leadership positions in marketing, product and business development and general management. His experience covered the spectrum of major therapeutic areas in pharmaceuticals plus a wide array of medical device markets in the U.S. and worldwide. As Group Vice President and General Manager, he was instrumental in the development and launch of several products that became major successes, with several achieving annual sales in excess of $1.0 billion each. Mr. Maglaris has been a member of a number of associations, including the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He is a past Trustee and Chair of the Board of Trustees of the University of Vermont, a past member and officer of the Board of Trustees of the New Canaan Country School and serves as Lead Director on the Board of Directors of the AmeriCares Foundation. He holds a B.S. degree from the University of Vermont (1967) and an MBA from Northeastern University (1975).
James J. Hamsher, PhD., Licensing and Business Development. Dr. Hamsher has more than 30 years of experience in the pharmaceutical industry. This experience includes several years in Pfizer's Central Research Division as a chemist and management responsibilities, followed by a successful career in Pfizer's Corporate Licensing and Development Division as a Senior Director. In this capacity, Dr. Hamsher was responsible for worldwide licensing activities that included the search for new drug entities, as well as negotiations necessary to conclude licensing agreements. Several new drug products were brought to market as a result of these activities. Following his retirement, Dr. Hamsher started a licensing consulting company and worked with several, small biotech and pharmaceutical companies. Dr. Hamsher received his Bachelor's Degree from Wabash College, his Master's Degree from Southern Illinois University, and his Ph.D. in Organic Chemistry from Purdue University.
Theodore Maione, Ph.D., Chief Scientific Officer. Dr. Maione has 22 years of experience in research, management and product development in the biotechnology industry. He has served as an officer at three companies that developed novel pharmaceutical products. Prior to joining Cytogel, Dr. Maione was the Chief Scientific Officer and Vice President of Research and Development at Seroptix. At Repligen, Dr. Maione held research and product development positions with responsibility for advancing novel therapeutic proteins and peptides from the lab into clinical development and also served as President and Chief Scientific Officer Repligen Development Corp. Dr. Maione previously also directed preclinical research for an amino acid prodrug that entered Phase III clinical trials for treatment of ARDS and SIRS at Transcend Therapeutics. Dr. Maione coordinates all Cytogel research and development efforts and has been instrumental in identifying Cytogel's primary products and creating its licensing and development strategy. Dr. Maione received a B.S. from Michigan State in 1978 and his Ph.D. from Cornell in 1983.